News | March 12, 2009

CATANIA Coronary Artery Stent Makes Live Case Debut During the Sociedad Venezolana de Cardiologia Intervencionista

March 12, 2009 - CeloNova BioSciences Inc. said yesterday physicians performing a live stent implantation during the annual scientific meeting of the Sociedad Venezolana de Cardiologia Intervencionista (SOVECI), March 13-14, elected to use the CATANIA Coronary Stent System with NanoThin Polyzene-F to demonstrate the benefits of this innovative new stent technology.

The procedure marks the first time the CATANIA stent was used in Venezuela.

"We are pleased to be the first physicians in Venezuela to treat a patient with the CATANIA stent. The fact that anti-platelet therapy can be discontinued after 30 days is a major benefit to patients who live in the rural areas of our country where travel and cost are important considerations," said Enrique Fermin M.D., president of SOVECI. "The clinical data also indicate that the CATANIA stent performs well in diabetic patients, which is a known significant health risk among the Venezuelan people."

Dr. Fermin, said his group elected to use the CATANIA Stent because it performed well in clinical trials. Results from the first-in-man study of the CATANIA stent in an unusually complex patient population showed zero percent stent thrombosis, death, myocardial infarction, stroke, or coronary artery bypass graft. Target lesion revascularization was 10.9 percent (only 3.6 percent clinically driven, 7.3 percent non-clinically driven), with a binary restenosis rate of 6.8 percent. Of note, all patients stopped dual anti-platelet therapy after 30 days. In a subset of 15 patients, an independent core lab analyzed vessel healing at six-months using optical coherence tomography (OCT) and found that 99.5 percent of stent struts were completely covered, suggesting complete endothelialization.

The CATANIA Coronary Stent System with NanoThin Polyzene-F represents a new class of stent featuring the latest in rapid-exchange, modified open-cell design and cobalt-chromium technology. The company said the CATANIA's unique combination of design and surface treatment offers many of the clinical benefits of drug-eluting stents, while addressing some of the significant ongoing concerns associated with DES options, including product cost, potential for thrombosis, and challenges associated with costly long-term dual anti-platelet therapy. The CATANIA stent carries a CE Mark and is currently available for sale outside the U.S. in 60 sizes, in lengths from 8-38mm and in diameters from 2-4 mm.

Polyzene-F, is a highly lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant surface treatment for implanted medical devices.

For more information:www.celonova.com

Related Content

The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents| November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents| November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents| November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents| October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents| November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents| November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
biosensors Biofreedom stent
News | Stents| November 07, 2016
November 7, 2016 – The two-year results from LEADERS FREE, the first randomized clinical trial dedicated to high blee
Overlay Init